Your browser is no longer supported. Please, upgrade your browser.
Vaccitech plc
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand34.06M Perf Week10.44%
Market Cap525.95M Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month7.22%
Income- PEG- EPS next Q- Inst Own- Short Float- Perf Quarter-
Sales4.82M P/S109.11 EPS this Y- Inst Trans- Short Ratio0.71 Perf Half Y-
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range12.25 - 17.99 Perf YTD9.50%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-14.17% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low26.04% ATR0.98
Employees48 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)57.72 Volatility5.59% 6.88%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.05 Prev Close15.19
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume243.56K Price15.44
Recom- SMA201.88% SMA505.00% SMA2005.00% Volume11,382 Change1.65%
May-25-21Initiated William Blair Outperform
May-25-21Initiated Morgan Stanley Overweight $22
May-25-21Initiated Jefferies Buy $28
May-24-21Initiated H.C. Wainwright Buy $25
Jun-01-21 08:00AM  
May-06-21 04:32PM  
May-04-21 05:07PM  
Apr-29-21 06:49PM  
Vaccitech plc is a clinical-stage biopharmaceutical company that engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. Its therapeutic programs include VTP-300, indicated for the treatment of chronic hepatitis B infection; VTP-200, indicated for the treatment of human papilloma virus infection; VTP-850, indicated for the treatment of prostate cancer; and VTP-600, indicated for the treatment of non-small cell lung cancer. The company's prophylactic programs include VTP-400 for the prevention of herpes zoster or shingles; and VTP-500 for the prevention of Middle East respiratory syndrome. In addition, it is developing AZD1222, a COVID-19 vaccine. Vaccitech plc was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc on March 31, 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DAWES KAREN ADirectorMay 04Buy17.001,70028,9001,700May 06 04:29 PM
Wright RobinDirectorMay 04Buy17.0014,000238,00024,506May 06 04:28 PM
Griffiths GrahamChief Business OfficerMay 04Buy17.001001,700100May 06 04:28 PM
Ellis ChristopherChief Operating OfficerMay 04Buy17.00751,27575May 06 04:27 PM
Scheeren JosephDirectorMay 04Buy17.003,00051,0003,000May 06 04:26 PM
Oxford Sciences Innovation plc10% OwnerMay 04Buy17.00600,00010,200,0008,797,770May 06 04:25 PM
Phillips Anne M.DirectorMay 04Buy17.003,00051,0003,000May 06 04:25 PM
M&G INVESTMENT MANAGEMENT LTD10% OwnerApr 30Buy14.40125,0001,800,0001,088,597May 03 03:20 PM